Exacerbation and myasthenic crisis in generalized myasthenia gravis: real-world healthcare resource utilization and cost burden in the United States

作者：Louis Jackson, Zhiwen Liu, Jacqueline Pesa, Alicia K. Campbell, Zia Choudhry, Alberto E. Batista, Nizar Souayah · 发表于：Current Medical Research and Opinion · 年份：2025 · DOI：10.1080/03007995.2025.2576597 · 被引用次数：3 · 研究领域：Myasthenia Gravis and Thymoma、Parkinson's Disease and Spinal Disorders、Coagulation, Bradykinin, Polyphosphates, and Angioedema

Objectives Healthcare resource utilization (HCRU) and cost assessments for generalized myasthenia gravis (gMG) rarely include matched controls. HCRU and costs of acute MG-related events (MG exacerbation and myasthenic crisis) have been examined, but aggregation or comparison between studies is limited by heterogeneity. The study aim was to provide comprehensive, real-world data about gMG patients in the United States, including those experiencing MG-related events. A claims database analysis assessed (i) incremental HCRU and cost burden among adults with gMG versus non-gMG controls, (ii) occurrence of MG-related events, (iii) HCRU and cost burden of MG-related events, and (iv) factors associated with MG-related events.Methods In this retrospective cohort study, adults with gMG in the United States were identified from Optum’s de-identified Clinformatics® Data Mart Database (1/1/2017–3/31/2023). Rates of MG-related events during follow-up were calculated. Regression models assessed associations between occurrence of MG-related events and baseline demographic/clinical variables using a nested case–control design embedded within the existing gMG cohort. Incremental HCRU and healthcare costs were compared between cohorts with/without gMG using the propensity score method with inverse probability of treatment weighting for confounding controls. Incremental HCRU and healthcare costs were also reported for gMG subgroups with/without MG-related events.Results Analyses included 16,561...